Scholar Rock Holding Corp (SRRK): Shareholders' Equity
$245.49M
As of 2025-12-31
$253.78M
As of 2026-06-30
-1.9%
3-year compound annual growth
-1.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $245.49M | -33.4% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $368.63M | +63.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $225.22M | -13.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $260.24M | +51.2% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $172.07M | -34.0% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $260.77M | +131.0% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $112.90M | +5.9% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $106.62M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | -$53.52M | n/a | 2019-03-19, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $245.49M | -33.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Amgen Inc (AMGN) | 2025-12-31 | $8.66B | +47.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Biogen Inc. (BIIB) | 2025-12-31 | $18.26B | +9.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $22.62B | +17.5% |
Compare SRRK, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗